Pharmacology, Toxicology and Pharmaceutical Science
Lung Cancer
100%
Non Small Cell Lung Cancer
99%
Epidermal Growth Factor Receptor
56%
Asthma
52%
Osimertinib
42%
Immune Checkpoint Inhibitor
41%
Chemotherapy
37%
Progression Free Survival
36%
Disease
34%
Adverse Event
31%
Overall Survival
29%
Monotherapy
29%
Neoplasm
23%
Clinical Trial
23%
Eosinophil Cationic Protein
22%
Cohort Study
21%
Pemetrexed
18%
Symptom
18%
Malignant Neoplasm
18%
Programmed Death 1 Ligand 1
17%
Docetaxel
16%
Coronavirinae
16%
Afatinib
14%
Sleep Disordered Breathing
14%
Pembrolizumab
14%
Pranlukast
13%
Interstitial Lung Disease
13%
Fibrosing Alveolitis
13%
Paclitaxel
13%
Epidermal Growth Factor Receptor Kinase Inhibitor
12%
Carboplatin
12%
Programmed Cell Death
11%
Chronic Obstructive Lung Disease
11%
Adenocarcinoma
11%
Phase II Trials
10%
SARS Coronavirus
10%
Leukotriene Receptor Blocking Agent
10%
Transforming Growth Factor
10%
Clinical Study
9%
Respiratory Tract Inflammation
9%
Retrospective Study
9%
Favipiravir
9%
Small Cell Lung Cancer
9%
Suplatast Tosylate
9%
Carcinoma
9%
Lung Tuberculosis
9%
Cachexia
9%
Immunotherapy
9%
Pneumonia
8%
Tumor Marker
8%
Squamous Cell Carcinoma
8%
Placebo
8%
Prevalence
8%
Brain Metastasis
7%
Transdermal
7%
Inflammation
7%
Febrile Neutropenia
7%
Lung Disease
7%
Combination Therapy
7%
Lung Adenocarcinoma
7%
Remdesivir
6%
Chemoradiation Therapy
6%
Comorbidity
6%
Allergic Asthma
6%
Beclometasone Dipropionate
6%
Bone Metastasis
6%
Receptor
6%
Cisplatin
5%
Protein P53
5%
Lung Fibrosis
5%
Anticarcinogen
5%
Observational Study
5%
Creatinine
5%
Syndrome
5%
Nivolumab
5%
Tumor Growth
5%
Small Cell Carcinoma
5%
Gefitinib
5%
Erlotinib
5%
Survival Rate
5%
Medicine and Dentistry
Non Small Cell Lung Cancer
65%
Lung Cancer
48%
COVID-19
35%
Immune Checkpoint Inhibitor
28%
Computer Assisted Tomography
22%
Chemoimmunotherapy
21%
Epidermal Growth Factor Receptor
19%
Osimertinib
18%
Monotherapy
15%
Retrospective Study
14%
Endobronchial Ultrasonography
13%
Transbronchial Biopsy
13%
Carcinoma
13%
Interstitial Lung Disease
13%
Disease
13%
Biopsy
12%
Clinical Trial
12%
Symptom
12%
Programmed Cell Death
12%
Progression Free Survival
12%
Immunotherapy
11%
Neoplasm
11%
Pemetrexed
10%
Overall Survival
10%
Cohort Analysis
10%
Favipiravir
9%
Asthma
9%
Immune-Related Adverse Events
9%
Amrubicin
9%
Gefitinib
9%
Brigatinib
9%
Positron Emission Tomography-Computed Tomography
9%
Cachexia
9%
Idiopathic Pulmonary Fibrosis
9%
Combination Therapy
9%
Drug Megadose
8%
Adenocarcinoma
8%
Small Cell Lung Cancer
8%
Maintenance Therapy
8%
Squamous Cell Carcinoma
8%
Placebo
7%
Epidermal Growth Factor Receptor Kinase Inhibitor
7%
Group Therapy
7%
Artery
7%
Diagnosis
6%
Ground Glass Opacity
6%
Immunohistochemistry
6%
Cytodiagnosis
6%
Bone Metastasis
6%
Oncogene
6%
Bronchoalveolar Lavage Fluid
6%
Severe Acute Respiratory Syndrome Coronavirus 2
6%
Silo-Filler's Disease
5%
Respiratory Failure
5%
Non-Small Cell Lung Cancer
5%
Bronchoscopy
5%
Low Drug Dose
5%
Afatinib
5%
Cytokeratin 19 Fragment
5%
Programmed Death 1 Ligand 1
5%
Sensitivity and Specificity
5%
Pneumonia
5%
Disease Severity
5%
Coronavirinae
5%
Liver Metastasis
5%
Cancer
5%
Infection
5%
Pneumothorax
5%
Peripheral Lung Lesion
5%
Keyphrases
Non-small Cell Lung Cancer (NSCLC)
40%
Immune Checkpoint Inhibitors
27%
Programmed Death-ligand 1 (PD-L1)
24%
Osimertinib
20%
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
17%
Overall Survival
14%
EGFR mutation
14%
Japanese Patients
14%
Monotherapy
13%
Brigatinib
13%
Chemotherapy
11%
Confidence Interval
11%
Phase II Trial
10%
International Journals
9%
Drug-induced Interstitial Lung Disease
9%
Pembrolizumab
9%
Clinical Oncology
9%
Elderly Patients
9%
Tyrosine Kinase Inhibitor
9%
COVID-19
9%
Previously Treated
9%
Pulmonary Pleomorphic Carcinoma
9%
ALK-positive Lung Cancer
9%
Non-elderly
9%
Inhalational Steroids
8%
Tumor Proportion Score
8%
Benign Nodule
8%
Docetaxel
7%
Transdermal Drugs
7%
Chemoimmunotherapy
7%
Hazard Ratio
7%
Lung Cancer
6%
Epidermal Growth Factor Receptor
6%
Progression-free Survival
6%
High-dose Steroids
6%
Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor (EGFR-TKI)
6%
Treatment Strategy
6%
Programmed Death-ligand 1 Expression
5%
Chronic Gastritis
5%
Afatinib
5%
Remdesivir
5%
Non-squamous NSCLC
5%
Tyrosine Kinase Inhibitor Therapy
5%
Performance Status
5%
Without Chemotherapy
5%
Clinical Factors
5%
Nab-paclitaxel
5%
Carbohydrate Antigen 19-9 (CA19-9)
5%
Matrix Expression
5%
Prognostic Impact
5%
Elderly People
5%